330 related articles for article (PubMed ID: 23566222)
1. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
[TBL] [Abstract][Full Text] [Related]
2. The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.
Hirai K; Nomura T; Yamasaki M; Inoue T; Narimatsu T; Chisato Nakada PD; Yoshiyuki Tsukamoto PD; Matsuura K; Sato F; Moriyama M; Mimata H
Urol Oncol; 2014 Feb; 32(2):101-9. PubMed ID: 23403204
[TBL] [Abstract][Full Text] [Related]
3. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
[TBL] [Abstract][Full Text] [Related]
4. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
5. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons LS; Rao S; Balkan W; Faysal J; Maiorino CA; Burnstein KL
Mol Endocrinol; 2008 Mar; 22(3):597-608. PubMed ID: 18079321
[TBL] [Abstract][Full Text] [Related]
6. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
7. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
Kim SM; Park JH; Kim KD; Nam D; Shim BS; Kim SH; Ahn KS; Choi SH; Ahn KS
Phytother Res; 2014 Mar; 28(3):423-31. PubMed ID: 23686889
[TBL] [Abstract][Full Text] [Related]
8. Pterostilbene-isothiocyanate conjugate suppresses growth of prostate cancer cells irrespective of androgen receptor status.
Nikhil K; Sharan S; Chakraborty A; Roy P
PLoS One; 2014; 9(4):e93335. PubMed ID: 24699278
[TBL] [Abstract][Full Text] [Related]
9. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
Ibuki N; Ghaffari M; Reuveni H; Pandey M; Fazli L; Azuma H; Gleave ME; Levitzki A; Cox ME
Mol Cancer Ther; 2014 Dec; 13(12):2827-39. PubMed ID: 25267499
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway.
Tan B; Li Y; Zhao Q; Fan L; Liu Y; Wang D; Zhao X
Cancer Gene Ther; 2014 Dec; 21(12):526-31. PubMed ID: 25430880
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
12. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.
Rao S; Lyons LS; Fahrenholtz CD; Wu F; Farooq A; Balkan W; Burnstein KL
Oncogene; 2012 Feb; 31(6):716-27. PubMed ID: 21765461
[TBL] [Abstract][Full Text] [Related]
13. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
14. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.
Liu Y; Mo JQ; Hu Q; Boivin G; Levin L; Lu S; Yang D; Dong Z; Lu S
Cancer Res; 2008 Aug; 68(15):6396-406. PubMed ID: 18676865
[TBL] [Abstract][Full Text] [Related]
15. The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells.
Liu Y; Wu X; Dong Z; Lu S
Int J Oncol; 2010 Mar; 36(3):623-33. PubMed ID: 20126983
[TBL] [Abstract][Full Text] [Related]
16. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
Song R; Harris LD; Pettaway CA
Prostate; 2010 May; 70(6):571-83. PubMed ID: 19938012
[TBL] [Abstract][Full Text] [Related]
17. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
18. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways.
Lu X; Yang F; Chen D; Zhao Q; Chen D; Ping H; Xing N
Int J Biol Sci; 2020; 16(7):1121-1134. PubMed ID: 32174789
[TBL] [Abstract][Full Text] [Related]
19. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
[TBL] [Abstract][Full Text] [Related]
20. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
